Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9482064 | 0.98 | MEN1 (0.57) | MEN1KMT2ALTA4HNPC1RAB9A | |
| SCHEMBL9702794 | 0.94 | MEN1 (0.58) | MEN1KMT2ALTA4HNPC1RAB9A | |
| Dimethylamine SCHEMBL3444783 | 0.94 | MEN1 (0.58) | MEN1KMT2ALTA4HNPC1RAB9A | |
| SCHEMBL3790721 | 0.91 | NPC1 (0.61) | MEN1KMT2ALTA4HNPC1RAB9A | |
| Diethylamine SCHEMBL3445370 | 0.90 | MEN1 (0.55) | MEN1KMT2ALTA4HNPC1RAB9A | |
| 1,4-Dipropoxybenzene SCHEMBL122039 | 0.87 | LTA4H (0.67) | MEN1KMT2ALTA4HNPC1RAB9A | |
| SCHEMBL6907235 | 0.86 | NR5A1 (0.62) | LTA4HNPC1RAB9ASMN1; SMN2DRD4 | |
| SCHEMBL9771562 | 0.85 | MEN1 (0.48) | MEN1KMT2ALTA4HNPC1RAB9A | |
| SCHEMBL21567534 | 0.85 | NPC1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9510047 | 0.85 | MCHR1 (0.51) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-118812565-A | Triazine derivative modified halogenated diphenyl pyrrolopyrrole dione compound and preparation method and application thereof | 山东凯瑞尔光电科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812566-A | Hyperbranched triazine modified pyrrolopyrrolidone compound as well as preparation method and application thereof | 山东凯瑞尔光电科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-3632892-B1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2024-07-31 | — | — | EP | disclosed |
| US-20230365493-A1 | COMPOUNDS AND METHODS | DemAgtech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| CN-110799490-B | 3-arylpropionamide compound and method for producing 3-arylpropionate compound | 住友化学株式会社 | 2023-05-02 | — | — | CN | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1319007-B9 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-1998017631-A2 | SUBSTITUTED OXIME-ETHERS AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | disclosed |
| US-5090994-A | HETEROCYCLIC COMPOUNDS AND HERBICIDAL COMPOSITIONS CONTAINING THE COMPOUNDS AS EFFECTIVE COMPONENTS | AGRO-KANESHO CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
| EP-0384973-A2 | Heterocyclic compounds, method for preparing the same and herbicidal compositions containing the compounds as effective components | AGRO-KANESHO CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| CN-1007153-B | PREPN. OF BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGY ACTIVITY | WARNER LAMBERT CO (US) | 1990-03-14 | — | — | CN | disclosed |
| CN-85109587-A | Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0140327-A2 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MEN1 3349/4885KMT2A 1755/4885LTA4H 3781/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | MEN1 491/4885KMT2A 912/4885LTA4H 2871/4885 |
| US-20230365493-A1 | COMPOUNDS AND METHODS | DDT, CYP19A1, CYP1A1 | MEN1 3436/4885KMT2A 218/4885LTA4H 1107/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | MEN1 3088/4885KMT2A 4270/4885LTA4H 1682/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | MEN1 582/4885KMT2A 1615/4885LTA4H 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.